

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## 上海復旦張江生物醫藥股份有限公司

**Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code:1349)**

### **INSIDE INFORMATION POSITIVE PROFIT ALERT**

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.\* (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Board wishes to inform the Shareholders and potential investors that based on the information currently available to the Company and the preliminary assessment from the Company’s management of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 (the “**Reporting Period**”), it is expected to record an unaudited net profit attributable to shareholders of the Company of approximately RMB60 million to RMB70 million during the Reporting Period, turning from losses into profits as compared with last year (six months ended 30 June 2022: unaudited net loss attributable to shareholders of the Company of approximately RMB36 million). The unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB50 million to RMB60 million (six months ended 30 June 2022: unaudited net loss attributable to shareholders of the Company after deducting the non-recurring profit or loss of approximately RMB46 million).

### **MAIN REASONS FOR THE ESTIMATED PROFIT FOR THE REPORTING PERIOD**

During the Reporting Period, it is expected to record an unaudited revenue of approximately RMB500 million to RMB550 million which increased by 84.33% to 102.76% as compared with the same period last year. It is mainly due to the external environment gradually being stabilized, the sales volume and terminal use of the medical products of the Group have gradually recovered so that sales of main products of the Group rebounded, which caused a significant increase in revenue compared with the same period of last year, resulting a corresponding improvement in other relevant financial data.

As at the date of this announcement, the Company is still in the process of preparing the interim results of the Group for the six months ended 30 June 2023. The information set out above is only based on a preliminary assessment by the Board with reference to the information currently available to it (including the consolidated management accounts which have not been finalized or reviewed by the Company's auditors or the audit committee). The interim results of the Group for the six months ended 30 June 2023 is expected to be published on 10 August 2023. Further announcement(s) will be made by the Company in due course if there is any update in this regard.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board

**Zhao Da Jun**

*Chairman*

As at the date on the publication of this announcement, the Board comprises:

Mr. Zhao Da Jun (Executive Director)

Ms. Xue Yan (Executive Director)

Mr. Shen Bo (Non-executive Director)

Ms. Yu Xiao Yang (Non-executive Director)

Mr. Wang Hong Guang (Independent Non-executive Director)

Mr. Lam Siu Wing (Independent Non-executive Director)

Mr. Xu Pei Long (Independent Non-executive Director)

Shanghai, the PRC

18 July 2023

*\* For identification purpose only*